---
title: "NEPTUNUS: NEP018 tablets have received the drug clinical trial approval notice"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/231182060.md"
description: "NEPTUNUS announced that its wholly-owned subsidiary Shenzhen NEPTUNUS Pharmaceutical Technology Research Institute has received approval from the National Medical Products Administration to conduct clinical trials of NEP018 tablets in patients with advanced malignant solid tumors. NEP018 tablets are a new type of tumor-targeted small molecule kinase inhibitor with independent intellectual property rights, demonstrating good inhibitory effects on gastrointestinal tumors, aimed at meeting clinical needs. The core patent of this project has been granted an invention patent"
datetime: "2025-03-10T08:31:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/231182060.md)
  - [en](https://longbridge.com/en/news/231182060.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/231182060.md)
---

# NEPTUNUS: NEP018 tablets have received the drug clinical trial approval notice

According to the Zhitong Finance APP, NEPTUNUS (000078.SZ) announced that its wholly-owned subsidiary Shenzhen NEPTUNUS Pharmaceutical Technology Research Institute Co., Ltd. (hereinafter referred to as "NEPTUNUS Pharmaceutical Research Institute") recently received the "Drug Clinical Trial Approval Notice" for NEP018 tablets issued by the National Medical Products Administration, agreeing to conduct clinical trials of this product as a monotherapy for advanced malignant solid tumors.

NEP018 tablets are a new type of tumor-targeted small molecule kinase inhibitor independently developed by the NEPTUNUS Pharmaceutical Research Institute, with independent intellectual property rights. Comprehensive preclinical studies have shown that NEP018 tablets have good selective inhibitory activity against the designed targets and exhibit good inhibitory effects on gastrointestinal tumors. The pharmacokinetic tissue distribution is concentrated in the gastrointestinal tract. Given that the current treatment for gastrointestinal tumors primarily relies on chemotherapy drugs supplemented with biological drugs for combination therapy, the development of this project can address the unmet clinical needs for targeted small molecule drugs in gastrointestinal tumors to some extent. The core patent for this project has been granted an invention patent authorization

### Related Stocks

- [000078.CN](https://longbridge.com/en/quote/000078.CN.md)
- [UTHR.US](https://longbridge.com/en/quote/UTHR.US.md)

## Related News & Research

- [08:13 ETContinuity Biosciences anuncia el primer ensayo clínico en humanos para el cáncer de páncreas](https://longbridge.com/en/news/287062849.md)
- [Lupin bets big on India's GLP-1 market & respiratory drugs](https://longbridge.com/en/news/287021542.md)
- [Spago Nanomedical Presents Tumorad(R) Clinical Data at the International ANZSNM 2026 Conference](https://longbridge.com/en/news/286726324.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [00:45 ETAraceli Biosciences Launches Endeavor® Live Cell for Ultra-High-Throughput Kinetic Imaging in AI-Driven Drug Discovery](https://longbridge.com/en/news/287006505.md)